Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
08 août 2023 09h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its new quantitative BCR-ABL 2.0 panel, with features...
Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven
03 août 2023 09h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces significant reductions in its cash-burn. For the six months ended...
Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023
01 août 2023 09h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that Q2-2023 revenues have increased to $3.5M in Q2-2023 from $2.8M...
Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy
14 juin 2023 09h49 HE
|
Precipio, Inc.
NEW HAVEN, Conn., June 14, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen Cytopenia panel as part of the diagnostic process for...
Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology
13 juin 2023 09h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., June 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that it has entered into a collaboration agreement with a NY-based...
Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
08 juin 2023 08h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it has entered into securities purchase agreements with...
Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects
07 juin 2023 09h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., June 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that several operational improvement initiatives which commenced at...
Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
22 mai 2023 11h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a...
Precipio Shares Growth Catalysts For HemeScreen
17 mai 2023 16h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 17, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be discussing on today’s shareholders call several growth catalysts that...
Precipio Announces Q1-2023 Shareholder Update Call
15 mai 2023 16h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2023 corporate update call on May 17th at 5:00 PM ET....